Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
33%
Ph not_applicable
1
33%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
N/ANon-phased studies
1(50.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Other(1)

Detailed Status

Completed1
unknown1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 11 (50.0%)
N/A1 (50.0%)

Trials by Status

completed133%
unknown133%
not_yet_recruiting133%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingnot_applicable

Measurements of Inflammation Induced by Allergen Inhalation Challenge in Mild Allergic Asthma

NCT06411886
unknown

Validation of the Analysis Methodology Behind the Use of Quantitative 18F-FDG PET/CT to Assess Lung Inflammation

NCT03312712
completedphase_1

Neutrophil Imaging in Healthy Subjects Following Lipopolysaccharide or Saline Challenge and in Subjects With Chronic Obstructive Pulmonary Disease

NCT02551614

Clinical Trials (3)

Showing 3 of 3 trials
NCT06411886Not Applicable

Measurements of Inflammation Induced by Allergen Inhalation Challenge in Mild Allergic Asthma

Not Yet Recruiting
NCT03312712

Validation of the Analysis Methodology Behind the Use of Quantitative 18F-FDG PET/CT to Assess Lung Inflammation

Unknown
NCT02551614Phase 1

Neutrophil Imaging in Healthy Subjects Following Lipopolysaccharide or Saline Challenge and in Subjects With Chronic Obstructive Pulmonary Disease

Completed

All 3 trials loaded

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
3